Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Simcere Pharmaceutical Group Ltd
2096Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets. The company also offers promotion services for pharmaceutical products. It has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize SIM0801 and other drugs in the Greater China region. In addition, the company engages in the manufacture of pharmaceutical ingredients; and property management business. Simcere Pharmaceutical Group Limited was founded in 1995 and is headquartered in Nanjing, China. Address: No. 699-18, Xuanwu Road, Nanjing, China, 210042
Analytics
Precio Objetivo de WallStreet
68.51 HKDRelación P/E
–Rentabilidad por dividendo
2.47 %Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave 2096
Análisis de dividendos 2096
Aumento del dividendo durante 5 años
–Crecimiento continuo
1 AñoRatio de pago medio en 5 años
47 %Tendencia del payout 2096
Valoración de la acción 2096
Finanzas 2096
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |